Who was studied?
A 66-year-old man with advanced intrahepatic cholangiocarcinoma who declined surgery and systemic anticancer therapies.
What does the publication report?
After radiation with GM-CSF, the liver lesion decreased by 15%, 36% and 53% at 3, 12 and 24 months, respectively. The lung lesion did not grow.
Safety findings
The public abstract does not provide a graded adverse-event analysis.
How should we interpret it?
This treatment omits checkpoint blockade and should not be equated with the original PRaG triplet. It remains a single observation.
Read the original source
This independently written summary was checked against the publicly available abstract. Selected figures, where included, are checked against the full publication. This is not a full-paper translation or a clinical recommendation.
Application of Immunoenhancing Radiotherapy in Treating Unresectable Intrahepatic Cholangiocarcinoma: A Case Report · DOI: 10.54457/DR.202401006
Educational reporting, not individualized medical advice. Discuss treatment decisions with your clinical team.